Safety and efficacy of mepolizumab in eosinophilic chronic obstructive pulmonary disease: a systematic review and meta-analysis
Abstract
ABSTRACT Introduction Up to 40% of patients with COPD have an eosinophilic phenotype, which increases the risk of acute exacerbations. Mepolizumab, an anti – IL-5 monoclonal antibody, has shown mixed results. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of mepolizumab 100 mg in eosinophilic COPD. Methods Following PRISMA and Cochrane guidelines, we searched PubMed, Embase, and Cochrane Central through 18 May 2025. Randomized controlled trials comparing mepolizumab 100 mg versus placebo in eosinophilic COPD were included. The primary outcome was the annualized rate of moderate or severe exacerbations. Data were pooled using random-effects models. Results Four RCTs (1,953 patients) were included. Mepolizumab reduced annualized rate of moderate or severe exacerbations (Rate Ratio 0.80; 95% CI: 0.73–0.89; p < 0.00001) and prolonged time to first exacerbation (HR 0.78; 95% CI: 0.69–0.88; p < 0.0001). Sensitivity analysis excluding METREX showed fewer exacerbations requiring ED visits or hospitalization (Rate Ratio 0.63; 95% CI: 0.46–0.86; p = 0.004). Patient-reported outcomes did not improve. Safety was favorable, with reduced serious adverse events, including deaths (RR 0.84; 95% CI: 0.73–0.98; p = 0.03). Conclusions Mepolizumab reduces exacerbations with good safety in eosinophilic COPD, though without improvement in quality-of-life outcomes.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,953 participants or records.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.